Using conservative doses for reasonable durations with breaks between cycles represents a prudent approach to risk management
Extra caution is appropriate in patients with active cancer, recent cancer, unexplained masses, unexplained weight loss, pregnancy, breastfeeding, known allergy to peptide products, active infection, immune compromise, significant liver or kidney disease, active inflammatory or autoimmune disease flares, unusual clotting history, uncontrolled cardiovascular disease, use of chemotherapy or immune-modifying biologic therapy, and competitive athletes subject to anti-doping rules
Most importantly, design studies to answer mechanistic questions (does the peptide activate the expected pathway?) before efficacy questions (does it improve venous function?)
If a customer does not routinely monitor their email and would prefer a phone call, they must let us know when placing an order
Third-Party Testing: We don't just say it